Tweet
J Infect Dis. 2016 Jul 28. pii: jiw335. [Epub ahead of print]
The Effect of Statin Use on Influenza Vaccine Effectiveness.
McLean HQ1, Chow BD1, VanWormer JJ1, King JP1, Belongia EA1.
Author information
Abstract
BACKGROUND:
Recent studies suggest that statin use may reduce influenza vaccine effectiveness (VE), but laboratory-confirmed influenza was not assessed.
METHODS:
Patients ≥45 years old presenting with acute respiratory illness were prospectively enrolled during the 2004-2005 through 2014-2015 influenza seasons. Vaccination and statin use were extracted from electronic records. Respiratory samples were tested for influenza.
RESULTS:
The analysis included 3285 adults: 1217 (37%) statin nonusers, 903 (27%) unvaccinated statin nonusers, 847 (26%) vaccinated statin users, and 318 (10%) unvaccinated statin users. Statin use modified VE and influenza risk for A(H3N2) infection (p=0.002), but not for A(H1N1)pdm09 or B (p=0.2 and 0.4, respectively). VE against A(H3N2) was 45% (95% confidence interval [CI]: 27, 59) among statin nonusers and -21 (CI: -84, 20) among statin users. Vaccinated statin users had significant protection against A(H1N1)pdm09 (VE=68%, CI: 19, 87) and type B (VE=48%, CI: 1, 73). Statin use did not significantly modify VE when stratified by prior season vaccination. In validation analyses, the use of other cardiovascular medications did not modify influenza VE.
CONCLUSIONS:
Statin use was associated with reduced VE against A(H3N2), but not A(H1N1)pdm09 or type B. Further research is needed to assess biologic plausibility and confirm these results.
? The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.
PMID: 27471318 DOI: 10.1093/infdis/jiw335
[PubMed - as supplied by publisher]
The Effect of Statin Use on Influenza Vaccine Effectiveness.
McLean HQ1, Chow BD1, VanWormer JJ1, King JP1, Belongia EA1.
Author information
Abstract
BACKGROUND:
Recent studies suggest that statin use may reduce influenza vaccine effectiveness (VE), but laboratory-confirmed influenza was not assessed.
METHODS:
Patients ≥45 years old presenting with acute respiratory illness were prospectively enrolled during the 2004-2005 through 2014-2015 influenza seasons. Vaccination and statin use were extracted from electronic records. Respiratory samples were tested for influenza.
RESULTS:
The analysis included 3285 adults: 1217 (37%) statin nonusers, 903 (27%) unvaccinated statin nonusers, 847 (26%) vaccinated statin users, and 318 (10%) unvaccinated statin users. Statin use modified VE and influenza risk for A(H3N2) infection (p=0.002), but not for A(H1N1)pdm09 or B (p=0.2 and 0.4, respectively). VE against A(H3N2) was 45% (95% confidence interval [CI]: 27, 59) among statin nonusers and -21 (CI: -84, 20) among statin users. Vaccinated statin users had significant protection against A(H1N1)pdm09 (VE=68%, CI: 19, 87) and type B (VE=48%, CI: 1, 73). Statin use did not significantly modify VE when stratified by prior season vaccination. In validation analyses, the use of other cardiovascular medications did not modify influenza VE.
CONCLUSIONS:
Statin use was associated with reduced VE against A(H3N2), but not A(H1N1)pdm09 or type B. Further research is needed to assess biologic plausibility and confirm these results.
? The Author 2016. Published by Oxford University Press for the Infectious Diseases Society of America.
PMID: 27471318 DOI: 10.1093/infdis/jiw335
[PubMed - as supplied by publisher]